CD27 and hematologic disorder: Due to the immune stimulatory potential, several CD27-targeting strategies, including agonistic mAbs and engineering intracellular domains in CAR-T cells, have been tested in preclinical models and clinical trials targeting solid or hematological malignancies [4, 5].